Advertisement
Research Article| Volume 28, ISSUE 7, P588-594, October 01, 1990

Effects of daily oral m-Chlorophenylpiperazine in elderly depressed patients initial experience with a serotonin agonist

DOI:https://doi.org/10.1016/0006-3223(90)90396-J
Effects of daily oral m-Chlorophenylpiperazine in elderly depressed patients initial experience with a serotonin agonist
Previous ArticleNeuroendocrinological investigations during sleep deprivation in depression II. Longitudinal measurement of thyrotropin, TH, cortisol, prolactin, GH, and LH during sleep and sleep deprivation
Next ArticleIntercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Six patients (mean age 62.5 ± 7.6 years) with major depression were treated for 2 weeks with the serotonin agonist m-chlorophenylpiperazine (m-CPP), 80 mg/day in a double-blind, placebo-controlled, crossover-design pilot study. Two patients showed clinically significant improvement in depressive symptoms during active drug treatment, whereas two others showed modest effects. All patients tolerated the drug, with no major side effects and no changes in vital signs or in liver, renal, thyroid, or hematological function. Further studies are needed to determine the characteristics of the possible antidepressant effects of m-CPP; such work may yield greater understanding of the role of serotonin in affective and other psychiatric disorders.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders.
        3rd ed rev. American Psychiatric Press, Washington1987
        • Åsberg M.
        • Schalling D.
        • Träskman-Bendz L.
        • Wägner A.
        Psychobiology of suicide, impulsivity, and related phenomena.
        in: Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. Raven, New York1987: 655-668
        • Coppen A.J.
        • Doogan D.P.
        Serotonin and its place in the pathogenesis of depression.
        J. Clin Psychiatry. 1988; 49 (Suppl): 4-11
        • Coppen A.
        • Prange Jr, A.J.
        • Whybrow P.C.
        • Noguera R.
        Abnormalities of indoleamines in affective disorders.
        Arch Gen Psychiatry. 1972; 26: 474-478
        • Fuller R.W.
        • Snoddy H.D.
        • Mason N.R.
        • Owen J.E.
        Disposition and pharmacological effects of m-chlorophenylpiperazine in rats.
        Neuropharmacology. 1981; 20: 155-162
        • Hamik A.
        • Peroutka S.J.
        1-(m-chlorophenyl)piperazine (m-CPP) interactions with neurotransmitter receptors in the human brain.
        Biol Psychiatry. 1989; 25: 569-575
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Kennett G.A.
        • Curzon G.
        Evidence that m-CPP may have behavioral effects mediated by central 5-HT1C receptors.
        Br J Pharmacol. 1988; 94: 137-147
        • Kennett G.A.
        • Whitton P.
        • Shah K.
        • Curzon G.
        Anxiogenic-like effects of m-CPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists.
        Eur J Pharmacol. 1989; 164: 445-454
        • Lawlor B.A.
        • Sunderland T.
        • Hill J.L.
        • et al.
        Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects.
        Psychiatry Res. 1989; 29: 1-10
        • Lawlor B.A.
        • Sunderland T.
        • Mellow A.M.
        • Hill J.L.
        • Molchan S.E.
        • Murphy D.L.
        Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease: A controlled study.
        Arch Gen Psychiatry. 1989; 46: 542-549
        • Mellow A.M.
        • Aulakh C.S.
        • Murphy D.L.
        Neuroendocrine effects of serotonergic agents: Applications to the study of central serotonin function in humans.
        in: Rech R.H. Gudelsky G.A. 5-HT Agonists as Psychoactive Drugs. NPP Books, Ann Arbor1988: 259-282
        • Mellow A.M.
        • Lawlor B.A.
        • Sunderland T.
        • Mueller E.A.
        • Molchan S.E.
        • Murphy D.L.
        A pilot clinical trial of m-chlorophenylpiperazine in depression.
        in: Presented at the America Psychiatric Association Meeting, Montreal, May1988
        • Meltzer H.Y.
        • Lowy M.T.
        The serotonin hypothesis of depression.
        in: Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. Raven, New York1987: 513-526
        • Morgan D.G.
        The dopamine and serotonin systems during aging in human and rodent brain: A brief review.
        Prog Neuropsychopharmacol Biol Psychiatry. 1987; 11: 153-157
        • Mueller E.A.
        • Murphy D.L.
        • Sunderland T.
        • Jones J.
        A new postsynaptic serotonin agonist for studies in humans.
        Psychopharmacol Bull. 1985; 21: 701-704
        • Mueller E.A.
        • Sunderland T.
        • Murphy D.L.
        Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist in humans.
        J Clin Endocrinol Metab. 1985; 61: 1179-1184
        • Mueller E.A.
        • Murphy D.L.
        • Sunderland T.
        Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans.
        Psychopharmacology. 1986; 89: 388-391
        • Murphy D.L.
        • Campbell I.C.
        • Costa J.L.
        The brain serotonergic system in the affective disorders.
        Prog Neuropsychopharmacol. 1978; 2: 5-31
        • Murphy D.L.
        • Mueller E.A.
        • Garrick N.A.
        • Aulakh C.S.
        Use of serotonergic agents in the clinical assessment of central serotonin function.
        J Clin Psychiatry. 1986; 47 (suppl): 9-15
        • Murphy D.L.
        • Mueller E.A.
        • Hill J.L.
        • Tolliver T.J.
        • Jacobsen F.M.
        Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers.
        Psychopharmacology. 1989; 98: 275-282
        • Murphy D.L.
        • Zohar J.
        • Benkelfat C.
        • Pato M.T.
        • Pigott T.A.
        • Insel T.R.
        Obsessive compulsive disorder as a 5-HT subsystem-related behavioural disorder.
        Br J Psychiatry. 1989; 155: 15-24
        • Peroutka S.J.
        • Switzer J.A.
        • Hamik A.
        Identification of 5-hydroxytryptamine-1D binding sites in human brain membranes.
        Synapse. 1989; 3: 61-66
        • Robinson D.S.
        • Alms D.R.
        • Shrotriya R.C.
        • Messina M.
        • Wickramaratne P.
        Serotonergic anxiolytics and treatment of depression.
        Psychopathology. 1989; 22: 27-36
        • Roy A.
        • Linnoila M.
        Suicidal behavior, impulsiveness and serotonin.
        Acta Psychiatr Scand. 1988; 78: 529-535
        • Schweizer E.E.
        • Amsterdam J.
        • Rickels K.
        • Kaplan M.
        • Droba M.
        Open trial of buspirone in the treatment of major depressive disorder.
        Psychopharmacol Bull. 1986; 22: 183-185
        • Sills M.A.
        • Lucki I.
        • Frazer A.
        Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated injection of either 5-MeODMT or m-CPP.
        Life Sci. 1985; 36: 2463-2469
        • Traber J.
        • Glaser T.
        5-HT1A receptor-related anxiolytics.
        Trends Pharmacol Sci. 1987; 8: 432-437
        • Van Praag H.M.
        New evidence of serotonin-deficient depressions.
        Neuropsychobiology. 1977; 3: 56-63
        • Van Praag H.M.
        • Kahn R.
        • Asnis G.M.
        • Lemus C.Z.
        • Brown S.L.
        Therapeutic indications for serotonin-potentiating compounds: A hypothesis.
        Biol Psychiatry. 1987; 22: 205-212
        • Willner P.
        Antidepressants and serotonergic neurotransmission: An integrative review.
        Psychopharmacology. 1985; 85: 387-404
        • Young R.
        • Glennon R.A.
        Second generation anxiolytics and serotonin.
        in: Rech R.H. Gudelsky G.A. 5-HT Agonists as Psychoactive Drugs. NPP Books, Ann Arbor1988: 239-258

      Article info

      Publication history

      Received in revised form: March 21, 1990
      Received: January 11, 1990

      Identification

      DOI: https://doi.org/10.1016/0006-3223(90)90396-J

      Copyright

      © 1990 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX